364 related articles for article (PubMed ID: 28103158)
1. Serotonin receptor targeted therapy for migraine treatment: an overview of drugs in phase I and II clinical development.
Barbanti P; Aurilia C; Egeo G; Fofi L; Palmirotta R
Expert Opin Investig Drugs; 2017 Mar; 26(3):269-277. PubMed ID: 28103158
[TBL] [Abstract][Full Text] [Related]
2. Targeting to 5-HT1F receptor subtype for migraine treatment: lessons from the past, implications for the future.
Mitsikostas DD; Tfelt-Hansen P
Cent Nerv Syst Agents Med Chem; 2012 Dec; 12(4):241-9. PubMed ID: 22934751
[TBL] [Abstract][Full Text] [Related]
3. Targeting the 5-HT
Huang PC; Yang FC; Chang CM; Yang CP
Prog Brain Res; 2020; 255():99-121. PubMed ID: 33008517
[TBL] [Abstract][Full Text] [Related]
4. The safety and efficacy of the 5-HT 1F receptor agonist lasmiditan in the acute treatment of migraine.
Raffaelli B; Israel H; Neeb L; Reuter U
Expert Opin Pharmacother; 2017 Sep; 18(13):1409-1415. PubMed ID: 28749698
[TBL] [Abstract][Full Text] [Related]
5. Is selective 5-HT
Rubio-Beltrán E; Labastida-Ramírez A; Villalón CM; MaassenVanDenBrink A
Pharmacol Ther; 2018 Jun; 186():88-97. PubMed ID: 29352859
[TBL] [Abstract][Full Text] [Related]
6. Lasmiditan for the treatment of migraine.
Capi M; de Andrés F; Lionetto L; Gentile G; Cipolla F; Negro A; Borro M; Martelletti P; Curto M
Expert Opin Investig Drugs; 2017 Feb; 26(2):227-234. PubMed ID: 28076702
[TBL] [Abstract][Full Text] [Related]
7. Migraine: pathophysiology, pharmacology, treatment and future trends.
Villalón CM; Centurión D; Valdivia LF; de Vries P; Saxena PR
Curr Vasc Pharmacol; 2003 Mar; 1(1):71-84. PubMed ID: 15320857
[TBL] [Abstract][Full Text] [Related]
8. Drugs targeting 5-hydroxytryptamine receptors in acute treatments of migraine attacks. A review of new drugs and new administration forms of established drugs.
Tfelt-Hansen PC; Pihl T; Hougaard A; Mitsikostas DD
Expert Opin Investig Drugs; 2014 Mar; 23(3):375-85. PubMed ID: 24289494
[TBL] [Abstract][Full Text] [Related]
9. Review of dose-response curves for acute antimigraine drugs: triptans, 5-HT1F agonists and CGRP antagonists.
Hougaard A; Tfelt-Hansen P
Expert Opin Drug Metab Toxicol; 2015; 11(9):1409-18. PubMed ID: 26095133
[TBL] [Abstract][Full Text] [Related]
10. Characterization of binding, functional activity, and contractile responses of the selective 5-HT
Rubio-Beltrán E; Labastida-Ramírez A; Haanes KA; van den Bogaerdt A; Bogers AJJC; Zanelli E; Meeus L; Danser AHJ; Gralinski MR; Senese PB; Johnson KW; Kovalchin J; Villalón CM; MaassenVanDenBrink A
Br J Pharmacol; 2019 Dec; 176(24):4681-4695. PubMed ID: 31418454
[TBL] [Abstract][Full Text] [Related]
11. Profiling lasmiditan as a treatment option for migraine.
Curto M; Cipolla F; Cisale GY; Capi M; Spuntarelli V; Guglielmetti M; Martelletti P; Lionetto L
Expert Opin Pharmacother; 2020 Feb; 21(2):147-153. PubMed ID: 31766908
[No Abstract] [Full Text] [Related]
12. Side effects associated with current and prospective antimigraine pharmacotherapies.
González-Hernández A; Marichal-Cancino BA; MaassenVanDenBrink A; Villalón CM
Expert Opin Drug Metab Toxicol; 2018 Jan; 14(1):25-41. PubMed ID: 29226741
[TBL] [Abstract][Full Text] [Related]
13. Targeted 5-HT
Vila-Pueyo M
Neurotherapeutics; 2018 Apr; 15(2):291-303. PubMed ID: 29488143
[TBL] [Abstract][Full Text] [Related]
14. Activation of 5-hydroxytryptamine1B/1D/1F receptors as a mechanism of action of antimigraine drugs.
Ramírez Rosas MB; Labruijere S; Villalón CM; Maassen Vandenbrink A
Expert Opin Pharmacother; 2013 Aug; 14(12):1599-610. PubMed ID: 23815106
[TBL] [Abstract][Full Text] [Related]
15. An introduction to migraine: from ancient treatment to functional pharmacology and antimigraine therapy.
Villalón CM; Centurión D; Valdivia LF; De Vries P; Saxena PR
Proc West Pharmacol Soc; 2002; 45():199-210. PubMed ID: 12434581
[TBL] [Abstract][Full Text] [Related]
16. Lasmiditan mechanism of action - review of a selective 5-HT
Clemow DB; Johnson KW; Hochstetler HM; Ossipov MH; Hake AM; Blumenfeld AM
J Headache Pain; 2020 Jun; 21(1):71. PubMed ID: 32522164
[TBL] [Abstract][Full Text] [Related]
17. The Role of 5-Hydroxytryptamine in the Pathophysiology of Migraine and its Relevance to the Design of Novel Treatments.
Villalón CM; VanDenBrink AM
Mini Rev Med Chem; 2017; 17(11):928-938. PubMed ID: 27465216
[TBL] [Abstract][Full Text] [Related]
18. Lasmiditan for the acute treatment of migraine.
DeJulio PA; Perese JK; Schuster NM; Oswald JC
Pain Manag; 2021 Sep; 11(5):437-449. PubMed ID: 33840206
[TBL] [Abstract][Full Text] [Related]
19. The 5-HT1F receptor agonist lasmiditan as a potential treatment of migraine attacks: a review of two placebo-controlled phase II trials.
Tfelt-Hansen PC; Olesen J
J Headache Pain; 2012 Jun; 13(4):271-5. PubMed ID: 22430431
[TBL] [Abstract][Full Text] [Related]
20. Preclinical studies characterizing the anti-migraine and cardiovascular effects of the selective 5-HT1D receptor agonist PNU-142633.
McCall RB; Huff R; Chio CL; TenBrink R; Bergh CL; Ennis MD; Ghazal NB; Hoffman RL; Meisheri K; Higdon NR; Hall E
Cephalalgia; 2002 Dec; 22(10):799-806. PubMed ID: 12485205
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
